TrialHuman vaccines & immunotherapeutics2024

Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.

Brandon J Essink et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.